Top

Published in:

01-07-2020 | Breast Cancer | Epidemiology

Overall health at diagnosis predicts the risk of complications within the first year after breast cancer diagnosis

Authors: Cecilia T. Ong, Yi Ren, Samantha M. Thomas, Ilona Stashko, Terry Hyslop, Gretchen Kimmick, Rachel C. Blitzblau, E. Shelley Hwang, Lars J. Grimm, Rachel A. Greenup

Published in: Breast Cancer Research and Treatment | Issue 2/2020

Abstract

Purpose

Breast cancer patients with overall poor health are at a greater risk of both complications during treatment and mortality from competing causes. We sought to determine the association of pre-existing comorbidities on treatment-related complications and overall survival.

Methods

We identified women ages 40–90 years old from our institutional registry with stage I–II invasive breast cancer from 2005 to 2014. Recursive partitioning was used to stratify women based on pre-existing comorbidities as low, moderate, or high risk of treatment-associated complications. Cox proportional hazards model was constructed to estimate the association of risk with overall survival.

Results

2077 women were studied. Mean age was 60 (IQR 51–68). Over half (54%) had ≥ 1 comorbid condition, and 29% experienced at least one adverse medical event within 1 year of diagnosis. Risk categories included low (no comorbidities or hypertension), moderate (combinations of comorbidities excluding congestive heart failure), and high (congestive heart failure in isolation or in combination with other conditions). High-risk women had a lower 10-year OS compared to moderate- or low-risk women (89% vs 90% vs 96%, log-rank p < 0.001). After adjustment, being at moderate (HR 2.20, 95% CI 1.30–3.72, p = 0.003) or high risk (HR 5.07, 95% CI 1.66–15.52, p = 0.004) of adverse sequelae was associated with reduced OS compared to those at low risk of these adverse medical events.

Conclusions

Following breast cancer diagnosis, overall poor health was associated with a greater risk of mortality and complications within the first year of treatment, which was driven by a pre-existing diagnosis of congestive heart failure.

Available only for authorised users

Greenlee RT, Murray T, Bolden S et al (2000) Cancer statistics, 2000. CA Cancer J Clin 50(1):7–33CrossRefPubMed

Guralnik JM (1996) Assessing the impact of comorbidity in the older population. Ann Epidemiol 6(5):376–380CrossRefPubMed

Aziz D, Gardner S, Pritchard K et al (2007) Selective application of axillary node dissection in elderly women with early breast cancer. Ann Surg Oncol 14(2):652–659. https://doi.org/10.1245/s10434-006-9092-y CrossRefPubMed

Yancik R, Ries LG, Yates JW (1989) Breast cancer in aging women. A population-based study of contrasts in stage, surgery, and survival. Cancer 63(5):976–981CrossRefPubMed

Yancik R, Havlik RJ, Wesley MN et al (1996) Cancer and comorbidity in older patients: a descriptive profile. Ann Epidemiol 6(5):399–412CrossRefPubMed

Satariano WA (1992) Comorbidity and functional status in older women with breast cancer: implications for screening, treatment, and prognosis. J Gerontol 47:24–31PubMed

Hutchins LF, Unger JM, Crowley JJ et al (1999) Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med 341(27):2061–2067. https://doi.org/10.1056/NEJM199912303412706 CrossRefPubMed

Lewis JH, Kilgore ML, Goldman DP et al (2003) Participation of patients 65 years of age or older in cancer clinical trials. J Clin Oncol 21(7):1383–1389. https://doi.org/10.1200/JCO.2003.08.010 CrossRefPubMed

Barthelemy P, Heitz D, Mathelin C et al (2011) Adjuvant chemotherapy in elderly patients with early breast cancer. Impact of age and comprehensive geriatric assessment on tumor board proposals. Crit Rev Oncol Hematol 79(2):196–204. https://doi.org/10.1016/j.critrevonc.2010.06.005 CrossRefPubMed

10.

El-Tamer MB, Ward BM, Schifftner T et al (2007) Morbidity and mortality following breast cancer surgery in women: national benchmarks for standards of care. Ann Surg 245(5):665–671. https://doi.org/10.1097/01.sla.0000245833.48399.9a CrossRefPubMedPubMedCentral

11.

Yood MU, Wells KE, Alford SH et al (2012) Cardiovascular outcomes in women with advanced breast cancer exposed to chemotherapy. Pharmacoepidemiol Drug Saf 21(8):818–827. https://doi.org/10.1002/pds.3239 CrossRefPubMedPubMedCentral

12.

Hershman DL, Shao T (2009) Anthracycline cardiotoxicity after breast cancer treatment. Oncology (Williston Park) 23(3):227–234

13.

Land LH, Dalton SO, Jensen MB et al (2012) Influence of comorbidity on the effect of adjuvant treatment and age in patients with early-stage breast cancer. Br J Cancer 107(11):1901–1907. https://doi.org/10.1038/bjc.2012.472 CrossRefPubMedPubMedCentral

14.

Onitilo AA, Kar P, Engel JM et al (2013) Long-term cardiac and vascular disease outcomes following adjuvant tamoxifen therapy: current understanding of impact on physiology and overall survival. Minerva Med 104(2):141–153PubMed

15.

Harris EE (2008) Cardiac mortality and morbidity after breast cancer treatment. Cancer Control 15(2):120–129. https://doi.org/10.1177/107327480801500204 CrossRefPubMed

16.

Ording AG, Garne JP, Nystrom PM et al (2013) Comorbid diseases interact with breast cancer to affect mortality in the first year after diagnosis–a Danish nationwide matched cohort study. PLoS ONE 8(10):e76013. https://doi.org/10.1371/journal.pone.0076013 CrossRefPubMedPubMedCentral

17.

Patnaik JL, Byers T, Diguiseppi C et al (2011) The influence of comorbidities on overall survival among older women diagnosed with breast cancer. J Natl Cancer Inst 103(14):1101–1111. https://doi.org/10.1093/jnci/djr188 CrossRefPubMedPubMedCentral

18.

Kimmick GG, Li X, Fleming ST et al (2018) Risk of cancer death by comorbidity severity and use of adjuvant chemotherapy among women with locoregional breast cancer. J Geriatr Oncol 9(3):214–220. https://doi.org/10.1016/j.jgo.2017.11.004 CrossRefPubMed

19.

Louwman WJ, Janssen-Heijnen ML, Houterman S et al (2005) Less extensive treatment and inferior prognosis for breast cancer patient with comorbidity: a population-based study. Eur J Cancer 41(5):779–785. https://doi.org/10.1016/j.ejca.2004.12.025 CrossRefPubMed

20.

Wu XC, Lund MJ, Kimmick GG et al (2012) Influence of race, insurance, socioeconomic status, and hospital type on receipt of guideline-concordant adjuvant systemic therapy for locoregional breast cancers. J Clin Oncol 30(2):142–150. https://doi.org/10.1200/JCO.2011.36.8399 CrossRefPubMed

21.

Extermann M (2000) Measuring comorbidity in older cancer patients. Eur J Cancer 36(4):453–471CrossRefPubMed

22.

Cronin-Fenton DP, Norgaard M, Jacobsen J et al (2007) Comorbidity and survival of Danish breast cancer patients from 1995 to 2005. Br J Cancer 96(9):1462–1468. https://doi.org/10.1038/sj.bjc.6603717 CrossRefPubMedPubMedCentral

23.

Bouchardy C, Rapiti E, Blagojevic S et al (2007) Older female cancer patients: importance, causes, and consequences of undertreatment. J Clin Oncol 25(14):1858–1869. https://doi.org/10.1200/JCO.2006.10.4208 CrossRefPubMed

24.

Van Leeuwen BL, Rosenkranz KM, Feng LL et al (2011) The effect of under-treatment of breast cancer in women 80 years of age and older. Crit Rev Oncol Hematol 79(3):315–320. https://doi.org/10.1016/j.critrevonc.2010.05.010 CrossRefPubMed

25.

Oncology SoS (2016) Choosing Wisely: American Board of Internal Medicine https://www.choosingwisely.org/societies/society-of-surgical-oncology/. Accessed 8 June 2019

26.

Rosenkranz KM, Bedrosian I, Feng L et al (2006) Breast cancer in the very elderly: treatment patterns and complications in a tertiary cancer center. Am J Surg 192(4):541–544. https://doi.org/10.1016/j.amjsurg.2006.06.019 CrossRefPubMed

27.

Mogal HD, Clark C, Dodson R et al (2017) Outcomes after mastectomy and lumpectomy in elderly patients with early-stage breast cancer. Ann Surg Oncol 24(1):100–107. https://doi.org/10.1245/s10434-016-5582-8 CrossRefPubMed

28.

Hughes KS, Schnaper LA, Bellon JR et al (2013) Lumpectomy plus tamoxifen with or without irradiation in women age 70 years or older with early breast cancer: long-term follow-up of CALGB 9343. J Clin Oncol 31(19):2382–2387. https://doi.org/10.1200/JCO.2012.45.2615 CrossRefPubMedPubMedCentral

29.

Hughes KS, Schnaper LA, Berry D et al (2004) Lumpectomy plus tamoxifen with or without irradiation in women 70 years of age or older with early breast cancer. N Engl J Med 351(10):971–977. https://doi.org/10.1056/NEJMoa040587 CrossRefPubMed

30.

Short ME, Goetzel RZ, Pei X et al (2009) How accurate are self-reports? Analysis of self-reported health care utilization and absence when compared with administrative data. J Occup Environ Med 51(7):786–796. https://doi.org/10.1097/JOM.0b013e3181a86671 CrossRefPubMedPubMedCentral

Title: Overall health at diagnosis predicts the risk of complications within the first year after breast cancer diagnosis
Authors: Cecilia T. Ong
Yi Ren
Samantha M. Thomas
Ilona Stashko
Terry Hyslop
Gretchen Kimmick
Rachel C. Blitzblau
E. Shelley Hwang
Lars J. Grimm
Rachel A. Greenup
Publication date: 01-07-2020
Publisher: Springer US
Keywords: Breast Cancer
Breast Cancer
Published in: Breast Cancer Research and Treatment / Issue 2/2020
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-020-05700-8

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 2/2020

Elevated MMP9 expression in breast cancer is a predictor of shorter patient survival

Somatic mutations of triple-negative breast cancer: a comparison between Black and White women

A comparison of two non-radioactive alternatives to wire for the localization of non-palpable breast cancers

Metabolic syndrome and early stage breast cancer outcome: results from a prospective observational study

Utilization patterns and temporal trends of internal mammary nodal irradiation at a tertiary cancer center

Predictive risk factors of complications in different breast reconstruction methods

Keynote webinar | Spotlight on antibody–drug conjugates in cancer